55. The UK&I National Neuromodulation Registry: an update on spinal cord stimulation for chronic neuropathic pain

Abstract

Background: The National Neuromodulation Registry (NNR) is a UK-wide repository of demographic, diagnostic, device identification, and quality-of-life (QoL) outcome data for patients undergoing SCS. It is governed by the Neuromodulation Society of the UK and Ireland (NSUKI), and operated by an independent third party (NEC Software Solutions UK). Large "real-world" datasets showing outcome after SCS for refractory severe neuropathic pain, complementing data from clinical trials, are an important endeavour. The initial NNR series has been accepted for publication; here we present an update with a further 12 month of follow up and new implant data, now including more than 2300 patients. Method(s): QoL (EuroQoL 5-dimension 5-level) and demographic data were extracted from the NNR, for patients treated between February 2018 and July 2023 in 27 UK centres. Those without recorded baseline EQ5D data were excluded. Follow-up timepoints were 6 and 12 months. Result(s): Of the 2308 included patients, 1263 (54.7%) were female, 1043 (45.2%) were male, and 2 undisclosed. The mean age at surgery was 52.4 years (sd=13.4 years). Median EQ5D utility index was significantly higher 6 months after surgery than before (0.548 [n=1313] vs. 0.263 [n=2308], p<<0.0001), and this change was sustained at 12 months after surgery (0.546 [n=1243] vs. 0.548 at 6 months [n=1313], p=0.22). Utility index increased by a mean of 0.205 (sd = 0.297 [n=1582]). 76.2% of patients had an improvement in EQ5D utility. Conclusion(s): SCS significantly improves QoL for patients with chronic neuropathic pain in a large prospective multicentre patient cohort. The NNR continues to show its value by demonstrating the effectiveness of SCS on a large scale. Copyright © 2025